Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma

15 Jan 2009

Abstract excerpt

PURPOSE: Despite objective response rates of only approximately 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma. The goal of this study was to identify molecular and/or genetic markers that correlate with, and could be used to predict, response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Glioma Diagnosis and Treatment
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19147755
DOI: 10.1158/1078-0432.ccr-08-1916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Molecular Profiling Predicts Response to Temozolomide in MelanomaPMID 19147755Read ↗

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeSemantic proximity Read ↗

MGMT Expression Predicts PARP-Mediated Resistance to TemozolomideSemantic proximity Read ↗

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivitySemantic proximity Read ↗

Sensitivity to temozolomide of cell lines derived from brain tumours and melanomas: relationship to MGMT gene expressionSemantic proximity Read ↗

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07Semantic proximity Read ↗

Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells.Semantic proximity Read ↗

Temozolomide in the Era of Precision MedicineSemantic proximity Read ↗

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideSemantic proximity Read ↗

Recent Approaches to Improve the Antitumor Efficacy of TemozolomideSemantic proximity Read ↗

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the<i>O</i>6-Methylguanine-DNA Methyltransferase PromoterSemantic proximity Read ↗

Circumventing Melanoma Chemoresistance by Targeting DNA RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.